comparemela.com

Calliditas Tel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU

BAD VILBEL, Germany and STOCKHOLM, Sept. 28, 2023 /PRNewswire/ Partners STADA and Calliditas Therapeutics.

Bad vilbelEuropean medicines agencyCommittee for medicinal products human useCalliditas therapeuticsNasdaq stockholmMedicinal productsHuman useInvestor relationsCalliditas telCreditor relationsstadastrasse

Calliditas - Year-End Report, 2022 (2)

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA.

United statesUnited kingdomMarie galayKidney internationalViatris pharmaceuticals japanViatris pharmaceuticals japan incEuropean commissionEuropean commission for kinpeygoExchange commissionAmerican society of nephrologyNational medical products administrationEuropean union member statesAmerican societyKidney weekEverest medicinesNew drug application

Calliditas - Year-End Report, 2022 (1)

"2022 was a fantastic year for Calliditas as we launched TARPEYO® in the US, the first approved drug for IgA.

United statesUnited kingdomMarie galayKidney internationalViatris pharmaceuticals japanViatris pharmaceuticals japan incEuropean commissionEuropean commission for kinpeygoExchange commissionAmerican society of nephrologyNational medical products administrationEuropean union member statesAmerican societyKidney weekEverest medicinesNew drug application

Calliditas to host fireside chat with its China commercial partner, Everest Medicines

STOCKHOLM, Dec. 9, 2022 /PRNewswire/ Calliditas Therapeutics AB (publ) ("Calliditas") today announced.

United statesRogers yongqing luoMarie galayZhengying zhuNational medical products administrationEuropean commissionEuropean union member statesEverest medicinesEastern timeCentral european timeChina standard timeChief medical officerInternal medicineGreater chinaSouth koreaNew drug application

vimarsana © 2020. All Rights Reserved.